ARA-290, also known as cibinetide or pHBSP (pyroglutamate helix B surface peptide), is an 11–amino acid peptide derived from the helix B region of erythropoietin (EPO). Unlike EPO, ARA-290 does not stimulate red blood cell production, focusing instead on tissue protection, anti-inflammation, and repair
Mechanism of Action
-
Innate Repair Receptor (IRR): ARA-290 selectively targets the IRR, a heteromeric complex composed of the erythropoietin receptor and the β-common (CD131) subunit. Activation of IRR triggers anti-inflammatory and tissue-repair pathways
-
TRPV1 Modulation: It also antagonizes TRPV1 (capsaicin receptor), which plays a key role in nociceptive pain signaling. This mechanism contributes to its analgesic (pain-relief) effects
Therapeutic Potential & Research Highlights
1. Small-Fiber Neuropathy (Sarcoidosis-Associated)
-
In controlled trials, 28 days of subcutaneous ARA-290 markedly improved neuropathic symptoms and autonomic dysfunction in sarcoidosis patients.
-
It also promoted regeneration of small nerve fibers in the cornea and enhanced exercise capacity (6-minute walk test)
2. Type 2 Diabetes with Neuropathy
-
In phase II studies, daily ARA-290 improved glycemic control (reduced HbA₁c), lipid profiles, neuropathic pain, and increased corneal nerve fiber density — without safety concerns
3. Anti-Inflammatory & Tissue-Protective Actions
-
Preclinical findings demonstrate that ARA-290 inhibits pro-inflammatory cytokines (e.g., TNF-α) and reduces apoptosis through IRR engagement. It accelerates wound healing, reduces scarring, and supports recovery across tissues
4. Neuropathic Pain Models
-
In animal models of sciatic nerve injury and neuropathic pain, ARA-290 reduces mechanical allodynia and cold sensitivity, demonstrating rapid and sustained relief. This effect is absent in animals lacking the β-common receptor, underscoring IRR’s role
-
A recent mouse study found that ARA-290 alleviates chronic stress-induced depression-like behavior. It appears to modulate the immune system and microglial activation, acting similarly to classical antidepressants but via distinct inflammatory pathways
-
A still more recent report reaffirms ARA-290’s continuing promise in reducing neuropathic pain and inflammation through mechanisms akin to those of EPO — without hematopoietic side effects
Summary Table
| Key Features | Details |
|---|---|
| Origin | 11-amino acid peptide derived from EPO (non-erythropoietic) |
| Mechanisms | Activates IRR (tissue-protective), antagonizes TRPV1 |
| Therapeutic Effects | Relief from neuropathic pain, improved nerve regeneration, metabolic benefits, anti-inflammation |
| Clinical Status | Phase II/III trials in neuropathy; orphan drug status for sarcoid neuropathy |
| Safety Profile | Favorable so far — minimal side effects reported in trials |
Reviews
There are no reviews yet.